ホモ接合性家族性高コレステロール血症治療の世界市場（～2026年）

• 英文タイトル：Global Homozygous Familial Hypercholesterolemia Treatment Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY01350 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料はホモ接合性家族性高コレステロール血症治療のグローバル市場について調査・分析したレポートです。種類別（AEM-2802、AEM-2814、アリロクマブ、エビナクマブ、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別ホモ接合性家族性高コレステロール血症治療の競争状況、市場シェア ・世界のホモ接合性家族性高コレステロール血症治療市場：種類別市場規模 2015年-2020年（AEM-2802、AEM-2814、アリロクマブ、エビナクマブ、その他） ・世界のホモ接合性家族性高コレステロール血症治療市場：種類別市場規模予測 2021年-2026年（AEM-2802、AEM-2814、アリロクマブ、エビナクマブ、その他） ・世界のホモ接合性家族性高コレステロール血症治療市場：用途別市場規模 2015年-2020年（クリニック、病院、その他） ・世界のホモ接合性家族性高コレステロール血症治療市場：用途別市場規模予測 2021年-2026年（クリニック、病院、その他） ・北米のホモ接合性家族性高コレステロール血症治療市場分析：米国、カナダ ・ヨーロッパのホモ接合性家族性高コレステロール血症治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのホモ接合性家族性高コレステロール血症治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のホモ接合性家族性高コレステロール血症治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのホモ接合性家族性高コレステロール血症治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：CymaBay Therapeutics Inc、Daewoong Co Ltd、Gemphire Therapeutics Inc、LipimetiX Development Inc、Regeneron Pharmaceuticals Inc、RegenxBio Inc、The Medicines Company ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market Analysis and Insights: Global Homozygous Familial Hypercholesterolemia Treatment Market
The global Homozygous Familial Hypercholesterolemia Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Homozygous Familial Hypercholesterolemia Treatment Scope and Market Size
Homozygous Familial Hypercholesterolemia Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Homozygous Familial Hypercholesterolemia Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Homozygous Familial Hypercholesterolemia Treatment market is segmented into
AEM-2802
AEM-2814
Alirocumab
Evinacumab
Others

Segment by Application, the Homozygous Familial Hypercholesterolemia Treatment market is segmented into
Clinic
Hospital
Others

Regional and Country-level Analysis
The Homozygous Familial Hypercholesterolemia Treatment market is analysed and market size information is provided by regions (countries).
The key regions covered in the Homozygous Familial Hypercholesterolemia Treatment market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Homozygous Familial Hypercholesterolemia Treatment Market Share Analysis
Homozygous Familial Hypercholesterolemia Treatment market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Homozygous Familial Hypercholesterolemia Treatment business, the date to enter into the Homozygous Familial Hypercholesterolemia Treatment market, Homozygous Familial Hypercholesterolemia Treatment product introduction, recent developments, etc.

The major vendors covered:
CymaBay Therapeutics Inc
Daewoong Co Ltd
Gemphire Therapeutics Inc
LipimetiX Development Inc
Regeneron Pharmaceuticals Inc
RegenxBio Inc
The Medicines Company
…

レポート目次

---

1 Study Coverage
1.1 Homozygous Familial Hypercholesterolemia Treatment Product Introduction
1.2 Market Segments
1.3 Key Homozygous Familial Hypercholesterolemia Treatment Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by Type
1.4.2 AEM-2802
1.4.3 AEM-2814
1.4.4 Alirocumab
1.4.5 Evinacumab
1.4.6 Others
1.5 Market by Application
1.5.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size, Estimates and Forecasts
2.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue 2015-2026
2.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales 2015-2026
2.2 Global Homozygous Familial Hypercholesterolemia Treatment, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Homozygous Familial Hypercholesterolemia Treatment Competitor Landscape by Players
3.1 Homozygous Familial Hypercholesterolemia Treatment Sales by Manufacturers
3.1.1 Homozygous Familial Hypercholesterolemia Treatment Sales by Manufacturers (2015-2020)
3.1.2 Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Manufacturers (2015-2020)
3.2 Homozygous Familial Hypercholesterolemia Treatment Revenue by Manufacturers
3.2.1 Homozygous Familial Hypercholesterolemia Treatment Revenue by Manufacturers (2015-2020)
3.2.2 Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Homozygous Familial Hypercholesterolemia Treatment Revenue in 2019
3.2.5 Global Homozygous Familial Hypercholesterolemia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Homozygous Familial Hypercholesterolemia Treatment Price by Manufacturers
3.4 Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base Distribution, Product Types
3.4.1 Homozygous Familial Hypercholesterolemia Treatment Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Homozygous Familial Hypercholesterolemia Treatment Product Type
3.4.3 Date of International Manufacturers Enter into Homozygous Familial Hypercholesterolemia Treatment Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size by Type (2015-2020)
4.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2015-2020)
4.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2015-2020)
4.1.3 Homozygous Familial Hypercholesterolemia Treatment Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Homozygous Familial Hypercholesterolemia Treatment Market Size Forecast by Type (2021-2026)
4.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Type (2021-2026)
4.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Type (2021-2026)
4.2.3 Homozygous Familial Hypercholesterolemia Treatment Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Homozygous Familial Hypercholesterolemia Treatment Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size by Application (2015-2020)
5.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2015-2020)
5.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2015-2020)
5.1.3 Homozygous Familial Hypercholesterolemia Treatment Price by Application (2015-2020)
5.2 Homozygous Familial Hypercholesterolemia Treatment Market Size Forecast by Application (2021-2026)
5.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Application (2021-2026)
5.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Application (2021-2026)
5.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Price Forecast by Application (2021-2026)

6 North America
6.1 North America Homozygous Familial Hypercholesterolemia Treatment by Country
6.1.1 North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country
6.1.2 North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Homozygous Familial Hypercholesterolemia Treatment Market Facts & Figures by Type
6.3 North America Homozygous Familial Hypercholesterolemia Treatment Market Facts & Figures by Application

7 Europe
7.1 Europe Homozygous Familial Hypercholesterolemia Treatment by Country
7.1.1 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country
7.1.2 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Homozygous Familial Hypercholesterolemia Treatment Market Facts & Figures by Type
7.3 Europe Homozygous Familial Hypercholesterolemia Treatment Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment by Region
8.1.1 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Region
8.1.2 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Facts & Figures by Type
8.3 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Facts & Figures by Application

9 Latin America
9.1 Latin America Homozygous Familial Hypercholesterolemia Treatment by Country
9.1.1 Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Country
9.1.2 Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Homozygous Familial Hypercholesterolemia Treatment Market Facts & Figures by Type
9.3 Central & South America Homozygous Familial Hypercholesterolemia Treatment Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment by Country
10.1.1 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country
10.1.2 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Market Facts & Figures by Type
10.3 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Market Facts & Figures by Application

11 Company Profiles
11.1 CymaBay Therapeutics Inc
11.1.1 CymaBay Therapeutics Inc Corporation Information
11.1.2 CymaBay Therapeutics Inc Description and Business Overview
11.1.3 CymaBay Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Products Offered
11.1.5 CymaBay Therapeutics Inc Related Developments
11.2 Daewoong Co Ltd
11.2.1 Daewoong Co Ltd Corporation Information
11.2.2 Daewoong Co Ltd Description and Business Overview
11.2.3 Daewoong Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Products Offered
11.2.5 Daewoong Co Ltd Related Developments
11.3 Gemphire Therapeutics Inc
11.3.1 Gemphire Therapeutics Inc Corporation Information
11.3.2 Gemphire Therapeutics Inc Description and Business Overview
11.3.3 Gemphire Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Products Offered
11.3.5 Gemphire Therapeutics Inc Related Developments
11.4 LipimetiX Development Inc
11.4.1 LipimetiX Development Inc Corporation Information
11.4.2 LipimetiX Development Inc Description and Business Overview
11.4.3 LipimetiX Development Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Products Offered
11.4.5 LipimetiX Development Inc Related Developments
11.5 Regeneron Pharmaceuticals Inc
11.5.1 Regeneron Pharmaceuticals Inc Corporation Information
11.5.2 Regeneron Pharmaceuticals Inc Description and Business Overview
11.5.3 Regeneron Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Products Offered
11.5.5 Regeneron Pharmaceuticals Inc Related Developments
11.6 RegenxBio Inc
11.6.1 RegenxBio Inc Corporation Information
11.6.2 RegenxBio Inc Description and Business Overview
11.6.3 RegenxBio Inc Sales, Revenue and Gross Margin (2015-2020)
11.6.4 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Products Offered
11.6.5 RegenxBio Inc Related Developments
11.7 The Medicines Company
11.7.1 The Medicines Company Corporation Information
11.7.2 The Medicines Company Description and Business Overview
11.7.3 The Medicines Company Sales, Revenue and Gross Margin (2015-2020)
11.7.4 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Products Offered
11.7.5 The Medicines Company Related Developments
11.1 CymaBay Therapeutics Inc
11.1.1 CymaBay Therapeutics Inc Corporation Information
11.1.2 CymaBay Therapeutics Inc Description and Business Overview
11.1.3 CymaBay Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Products Offered
11.1.5 CymaBay Therapeutics Inc Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Homozygous Familial Hypercholesterolemia Treatment Market Estimates and Projections by Region
12.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Regions 2021-2026
12.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Regions 2021-2026
12.2 North America Homozygous Familial Hypercholesterolemia Treatment Market Size Forecast (2021-2026)
12.2.1 North America: Homozygous Familial Hypercholesterolemia Treatment Sales Forecast (2021-2026)
12.2.2 North America: Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast (2021-2026)
12.2.3 North America: Homozygous Familial Hypercholesterolemia Treatment Market Size Forecast by Country (2021-2026)
12.3 Europe Homozygous Familial Hypercholesterolemia Treatment Market Size Forecast (2021-2026)
12.3.1 Europe: Homozygous Familial Hypercholesterolemia Treatment Sales Forecast (2021-2026)
12.3.2 Europe: Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast (2021-2026)
12.3.3 Europe: Homozygous Familial Hypercholesterolemia Treatment Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Homozygous Familial Hypercholesterolemia Treatment Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Homozygous Familial Hypercholesterolemia Treatment Market Size Forecast by Region (2021-2026)
12.5 Latin America Homozygous Familial Hypercholesterolemia Treatment Market Size Forecast (2021-2026)
12.5.1 Latin America: Homozygous Familial Hypercholesterolemia Treatment Sales Forecast (2021-2026)
12.5.2 Latin America: Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast (2021-2026)
12.5.3 Latin America: Homozygous Familial Hypercholesterolemia Treatment Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Homozygous Familial Hypercholesterolemia Treatment Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Homozygous Familial Hypercholesterolemia Treatment Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Homozygous Familial Hypercholesterolemia Treatment Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Homozygous Familial Hypercholesterolemia Treatment Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Homozygous Familial Hypercholesterolemia Treatment Market Segments
Table 2. Ranking of Global Top Homozygous Familial Hypercholesterolemia Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of AEM-2802
Table 5. Major Manufacturers of AEM-2814
Table 6. Major Manufacturers of Alirocumab
Table 7. Major Manufacturers of Evinacumab
Table 8. Major Manufacturers of Others
Table 9. Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Homozygous Familial Hypercholesterolemia Treatment Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Regions (2015-2020)
Table 13. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Homozygous Familial Hypercholesterolemia Treatment Sales Share by Manufacturers (2015-2020)
Table 16. Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Homozygous Familial Hypercholesterolemia Treatment by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Homozygous Familial Hypercholesterolemia Treatment as of 2019)
Table 18. Homozygous Familial Hypercholesterolemia Treatment Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Homozygous Familial Hypercholesterolemia Treatment Price (2015-2020) (USD/Pcs)
Table 21. Homozygous Familial Hypercholesterolemia Treatment Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Homozygous Familial Hypercholesterolemia Treatment Product Type
Table 23. Date of International Manufacturers Enter into Homozygous Familial Hypercholesterolemia Treatment Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2015-2020) (K Pcs)
Table 26. Global Homozygous Familial Hypercholesterolemia Treatment Sales Share by Type (2015-2020)
Table 27. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Type (2015-2020)
Table 29. Homozygous Familial Hypercholesterolemia Treatment Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2015-2020) (K Pcs)
Table 31. Global Homozygous Familial Hypercholesterolemia Treatment Sales Share by Application (2015-2020)
Table 32. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2015-2020) (K Pcs)
Table 33. North America Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2015-2020)
Table 34. North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country (2015-2020)
Table 36. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2015-2020) (K Pcs)
Table 37. North America Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2015-2020)
Table 38. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2015-2020) (K Pcs)
Table 39. North America Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2015-2020)
Table 40. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2015-2020)
Table 42. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country (2015-2020)
Table 44. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2015-2020)
Table 46. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2015-2020)
Table 56. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country (2015-2020)
Table 60. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2015-2020)
Table 62. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2015-2020)
Table 72. CymaBay Therapeutics Inc Corporation Information
Table 73. CymaBay Therapeutics Inc Description and Major Businesses
Table 74. CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. CymaBay Therapeutics Inc Product
Table 76. CymaBay Therapeutics Inc Recent Development
Table 77. Daewoong Co Ltd Corporation Information
Table 78. Daewoong Co Ltd Description and Major Businesses
Table 79. Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Daewoong Co Ltd Product
Table 81. Daewoong Co Ltd Recent Development
Table 82. Gemphire Therapeutics Inc Corporation Information
Table 83. Gemphire Therapeutics Inc Description and Major Businesses
Table 84. Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Gemphire Therapeutics Inc Product
Table 86. Gemphire Therapeutics Inc Recent Development
Table 87. LipimetiX Development Inc Corporation Information
Table 88. LipimetiX Development Inc Description and Major Businesses
Table 89. LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. LipimetiX Development Inc Product
Table 91. LipimetiX Development Inc Recent Development
Table 92. Regeneron Pharmaceuticals Inc Corporation Information
Table 93. Regeneron Pharmaceuticals Inc Description and Major Businesses
Table 94. Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Regeneron Pharmaceuticals Inc Product
Table 96. Regeneron Pharmaceuticals Inc Recent Development
Table 97. RegenxBio Inc Corporation Information
Table 98. RegenxBio Inc Description and Major Businesses
Table 99. RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. RegenxBio Inc Product
Table 101. RegenxBio Inc Recent Development
Table 102. The Medicines Company Corporation Information
Table 103. The Medicines Company Description and Major Businesses
Table 104. The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 105. The Medicines Company Product
Table 106. The Medicines Company Recent Development
Table 107. Global Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Regions (2021-2026) (K Pcs)
Table 108. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share Forecast by Regions (2021-2026)
Table 109. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 110. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share Forecast by Regions (2021-2026)
Table 111. North America: Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Country (2021-2026) (K Pcs)
Table 112. North America: Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 113. Europe: Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Country (2021-2026) (K Pcs)
Table 114. Europe: Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 115. Asia Pacific: Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Region (2021-2026) (K Pcs)
Table 116. Asia Pacific: Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Region (2021-2026) (US$ Million)
Table 117. Latin America: Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Country (2021-2026) (K Pcs)
Table 118. Latin America: Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 119. Middle East and Africa: Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Country (2021-2026) (K Pcs)
Table 120. Middle East and Africa: Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 121. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 122. Key Challenges
Table 123. Market Risks
Table 124. Main Points Interviewed from Key Homozygous Familial Hypercholesterolemia Treatment Players
Table 125. Homozygous Familial Hypercholesterolemia Treatment Customers List
Table 126. Homozygous Familial Hypercholesterolemia Treatment Distributors List
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of Figures
Figure 1. Homozygous Familial Hypercholesterolemia Treatment Product Picture
Figure 2. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type in 2020 & 2026
Figure 3. AEM-2802 Product Picture
Figure 4. AEM-2814 Product Picture
Figure 5. Alirocumab Product Picture
Figure 6. Evinacumab Product Picture
Figure 7. Others Product Picture
Figure 8. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application in 2020 & 2026
Figure 9. Clinic
Figure 10. Hospital
Figure 11. Others
Figure 12. Homozygous Familial Hypercholesterolemia Treatment Report Years Considered
Figure 13. Global Homozygous Familial Hypercholesterolemia Treatment Market Size 2015-2026 (US$ Million)
Figure 14. Global Homozygous Familial Hypercholesterolemia Treatment Sales 2015-2026 (K Pcs)
Figure 15. Global Homozygous Familial Hypercholesterolemia Treatment Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2015-2020)
Figure 17. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region in 2019
Figure 18. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region (2015-2020)
Figure 19. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region in 2019
Figure 20. Global Homozygous Familial Hypercholesterolemia Treatment Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Homozygous Familial Hypercholesterolemia Treatment Revenue in 2019
Figure 22. Homozygous Familial Hypercholesterolemia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2015-2020)
Figure 24. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type in 2019
Figure 25. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2015-2020)
Figure 26. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type in 2019
Figure 27. Global Homozygous Familial Hypercholesterolemia Treatment Market Share by Price Range (2015-2020)
Figure 28. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2015-2020)
Figure 29. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application in 2019
Figure 30. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2015-2020)
Figure 31. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application in 2019
Figure 32. North America Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country in 2019
Figure 35. North America Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country in 2019
Figure 36. U.S. Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Homozygous Familial Hypercholesterolemia Treatment Market Share by Type in 2019
Figure 41. North America Homozygous Familial Hypercholesterolemia Treatment Market Share by Application in 2019
Figure 42. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country in 2019
Figure 45. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country in 2019
Figure 46. Germany Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Homozygous Familial Hypercholesterolemia Treatment Market Share by Type in 2019
Figure 57. Europe Homozygous Familial Hypercholesterolemia Treatment Market Share by Application in 2019
Figure 58. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region in 2019
Figure 61. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region in 2019
Figure 62. China Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Share by Type in 2019
Figure 85. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Share by Application in 2019
Figure 86. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country in 2019
Figure 89. Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country in 2019
Figure 90. Mexico Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Homozygous Familial Hypercholesterolemia Treatment Market Share by Type in 2019
Figure 97. Latin America Homozygous Familial Hypercholesterolemia Treatment Market Share by Application in 2019
Figure 98. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country in 2019
Figure 102. Turkey Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Market Share by Type in 2019
Figure 109. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Market Share by Application in 2019
Figure 110. North America Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed

---